Clinical trials in Kortrijk – page 2

173 clinical trials in Kortrijk, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kortrijk at a glance

173

clinical trials

Paediatric trials0
Research sites0

Quick filters

173 trials in Kortrijk

Open in trial search

Atrial fibrillation+1

Recruiting

Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Registered drugNo placebo

Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Flecainide Acetate
Sponsor:UZ Leuven

Contact Research Centre

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Obesity+1

Recruiting

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Multiple sclerosis

Recruiting

A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

InvestigationalNo placebo

A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

InvestigationalNo placebo

Belgium

Participants:18–64 years
Substances:Frexalimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Follicle centre lymphoma follicular grade I, II - III

Recruiting

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Iron deficiency+1

Recruiting

A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

Registered drug

A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Ziekenhuis Oost Limburg

Contact Research Centre

Ovarian cancer

Recruiting

A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

InvestigationalNo placebo

A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:INCB123667
Sponsor:Incyte Corp.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Kortrijk

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple cancer types, including advanced research in prostate cancer, melanoma, and breast cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for improved patient outcomes.

Metastatic Prostate Cancer
Breast Cancer Therapies
Melanoma Treatments
Multiple Myeloma

Research emphasizes personalized treatment approaches and combination therapies to enhance effectiveness.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and related conditions, including trials for stroke prevention, atrial fibrillation, and coronary artery disease management.

Stroke Prevention
Atrial Fibrillation
Deep Vein Thrombosis
Coronary Artery Disease

Focus on innovative therapeutic approaches and preventive strategies for cardiovascular conditions.

03 Neurological & Chronic Conditions

Studies investigating treatments for neurological disorders and chronic conditions, including Alzheimer's disease, chronic kidney disease, and viral infections.

Alzheimer's Disease
Chronic Kidney Disease
Viral Lung Infections
Hepatitis B

Research aimed at developing effective treatments and improving patient quality of life.

Back to Belgium All countries